As measles cases continue to rise in the United States and globally, NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals, has announced progress in its NV-387 measles treatment program. The company is developing a Phase II clinical trial protocol and plans to bring it under U.S. Food and Drug Administration (FDA) review through an Investigational New Drug (IND) process.
NV-387 has already demonstrated strong in vivo activity against lethal measles infection in a humanized animal model, according to the company. It has also received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Drug Designation (RPDD) from the FDA for the treatment of measles. The RPDD status could make NanoViricides eligible for a Priority Review Voucher upon approval of a qualifying marketing application, provided applicable requirements are met. This voucher can be sold or transferred, potentially providing significant financial benefits.
The announcement comes at a time when measles, a highly contagious viral disease, is making a resurgence in parts of the U.S. and other countries, largely due to gaps in vaccination coverage. If left untreated, measles can lead to severe complications, especially in children, including pneumonia, encephalitis, and even death. Currently, there is no specific antiviral treatment for measles; supportive care is the standard approach.
NanoViricides' lead drug candidate, NV-387, is a broad-spectrum antiviral designed to treat multiple viral infections, including respiratory syncytial virus (RSV), COVID-19, influenza, and other respiratory viruses, as well as MPOX/smallpox and measles. The company's host-mimetic nanomedicine technology aims to trick viruses into binding to nanomicelles that mimic host cells, thereby neutralizing them and preventing infection.
The potential impact of an effective measles treatment is significant. While vaccination remains the primary prevention strategy, an antiviral could provide a crucial therapeutic option for those who contract the disease, especially in outbreak settings or for immunocompromised individuals who cannot be vaccinated. It could also help reduce the burden on healthcare systems during outbreaks.
NanoViricides has a broad pipeline addressing various viral diseases, including herpes, influenza, HIV, and Ebola, among others. The company's business model relies on licensing its nanomedicine technology from TheraCour Pharma, Inc., with exclusive rights for certain applications.
The path to regulatory approval is lengthy and capital-intensive, as the company acknowledges. Success in preclinical models does not guarantee similar outcomes in human trials. However, the FDA designations provide incentives and potential expedited review pathways, which could accelerate development.
For more information on the full press release, visit https://ibn.fm/JFyfZ.
